Leung, Bonnie
Shokoohi, Aria
Al-Hashami, Zamzam
Moore, Sara
Pender, Alexandra
Wong, Selina K.
Wang, Ying
Wu, Jonn
Ho, Cheryl
Article History
Received: 24 November 2022
Accepted: 31 March 2023
First Online: 19 April 2023
Declarations
:
: This retrospective study received approval from the local institutional research ethics board (University of British Columbia - BC Cancer Research Ethics Board; H15-02509) and approval for a waiver of consent to extract and analyze the archival data from the database. This research was conducted in accordance with relevant guidelines and local regulation.
: Not Applicable.
: Bonnie Leung reports receiving personal fees from AstraZeneca, outside of the submitted work. Cheryl Ho reports receiving personal fees from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, and Takeda; all outside of the submitted work. Ying Wang reports receiving personal fees from AstraZeneca, Merck, and Takeda; all outside of the submitted work. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.